Between 20 to 25% of Crohn's disease (CD) patients suffer from perianal fistulas, a marker
of disease severity. Seton drainage combined with anti-TNFα can result in closure of the …

Purpose The management of perianal fistula in patients with Crohn's disease is an
extremely challenging medical problem as many fistulas do not respond to available …

Aim Many perianal fistulae in Crohn's disease do not respond to conventional surgical and
medical management and recurrence rates are high. The study evaluated the safety and …

Background Crohn's fistula-in-ano is a refractory disease in colorectal and anal surgery.
Although autologous adipose-derived stem cell (ADSC) has been used in the treatment of …

Aim Even with optimal medical and surgical therapy, perianal fistulas in patients with
Crohn's disease (CD) have low closure rates. As a new therapeutic option, administration of …

Purpose Injection of adipose tissue-derived stem cells (ASCs) is a novel method for the
treatment of complex perianal fistulas. We aimed to evaluate the safety and efficacy of ASCs …

A previous phase II clinical trial of adipose-derived stem cell (ASC) therapy for fistulae
associated with Crohn's disease, a devastating condition with a high recurrence rate …

Aim Remission rates of medically and surgically treated complex perianal fistulas in Crohn's
disease are low. Recently, trials have demonstrated the potential for long‐term remission …

BACKGROUND: Anal fistula treatment aims to eradicate the fistula, preserve the sphincter,
prevent recurrence, and allow an early return to daily activities for the patient. Because of the …

From 30 to 70% of patients with Crohn's disease (CD) may develop perianal fistulas during
their lifetime. The medical and surgical management of this complication is challenging, and …